The Endocannabinoid System is one of the most expressed systems within the human body despite being one of the least studied, especially for the stigma still existing around the word Cannabis. Among its multiple functions, the Endocannabinoid System also participates in the regulation of the gastrointestinal tract. In this article, we discuss its functioning and how it could be useful in the treatment of numerous gastrointestinal disorders, like gastric reflux, obesity, chronic inflammation and motility disorders.
The discovery of the Endocannabinoid System in the gastrointestinal tract
The most important function of the gastrointestinal (GI) system is the digestion of food. Through a meticulous series of processes in the GI tract, food is transformed into the energy necessary to perform the various functions of life. This is one of the fundamental features of animal biology and the Endocannabinoid System (ECS) is fully involved in regulating this process.
The first report of the presence of the ECS in the mammalian GI system dates back to 1995, when a group of Israeli scientists, led by Raphael Mechulam - the same who first identified the THC - isolated an endocannabinoid, the 2-arachidonoylglycerol (2-AG), in the canine intestine. (1) Another endocannabionoid, the Anandamide, was later identified in the mouse intestine. (2) Subsequently, components of the ECS were identified in every portion of the mammalian GI system.
CB1 receptors are present practically everywhere, especially in the stomach and colon, the terminal portion of the intestine. (3) Here, they are mainly found on epithelial cells, the lining cells of the intestinal wall. CB1 receptors are also found on neurons that control the activities of the GI system, especially those of the Enteric Nervous System. (4)
CB2 receptors are also present in the Enteric Nervous System, but they are mainly found on the immune cells in the GI tract. (4)
The enzymes responsible for the production and degradation of cannabinoid, have also been found along the entire GI tract. (5) Here, we can also find Palmitoylethanolamide (PEA), Oleoylethanolamide (OEA) and other similar compounds. (5) These molecules, although not acting directly on CB1 or CB2 receptors, behave in the same way as endocannabinoids -they are defined as cannabinoid-like compounds (cannabimimetics)- and play an important role in the GI system, especially in preventing the onset of inflammation. (6)
The Endocannabinoid System and the gastrointestinal homeostasis
Once ingested, the food have to be metabolized to give nourishment. If we follow the path of food along the GI tract, we can easily appreciate how the ECS is able to regulate the GI system.
After being shredded in the mouth, food passes into the esophagus. From here, through an elastic opening called esophageal sphincter, food reaches the stomach. Relaxation of the esophageal sphincter is one of the main causes of gastroesophageal reflux, a pathology that affects approximately 20% of adults in the western culture, at least once a month. (7).
In a 2009 clinical study on healthy volunteers, daily administration of 10 or 20 milligrams of tetrahydrocannabinol (THC) was able to decrease relaxation of the esophageal sphincter and consequently all the symptoms of reflux. (8) Experiments on animal models have shown that this effect is mainly due to the activation of CB1 receptors. (9)
A protection for the stomach
Once in the stomach, the food is further reduced in size by the action of the hydrochloric acid, secreted by the cells of the gastric wall. An abnormal production of hydrochloric acid causes the so-called "heartburn" which, in severe cases, can result in gastritis or in ulcerations (lesions of the gastric wall).
Even before the identification of cannabinoid receptors, a group of US scientists noted that by administering THC to rats with gastric ulcers induced by anti-inflammatory drugs, gastric secretion and especially the degree of ulcer formation was reduced - thus highlighting the gastroprotective effect cannabinoids. (10)
The ECS not only protects against ulcers caused by drugs. In 2003, a group of Italian pharmacologists discovered that the activation of the CB1 receptor was able to reduce the gastric secretion induced by the cholera toxin. (11)
The activation of the CB1 receptor in the stomach can also slow down the gastric emptying. (12) This effect of the CB1 can be exploited in case of gastroparesis, a chronic pathology consisting of partial paralysis of the stomach, with consequent delay in emptying. In people suffering from gastroparesis, the stomach empties more slowly and this can lead to loss of appetite, nausea and even vomiting. Currently, there is no specific cure for this pathology, but the use of drugs that contrast the action of cannabinoids, the so-called antagonists, could prove to be an effective strategy.
The "brakes" of the intestine
From the stomach, food must then travel all over the intestine, so that the nutrients can be absorbed, while any waste eliminated. This occurs through a movement of the intestinal wall called peristalsis, a series of contractions and relaxations that, like a pump, push food from the duodenum, the initial portion of the intestine, to the colon.
A defect of the intestinal motility is the hypermotility, a condition not yet fully understood (it is usually associated with an increased intestinal inflammation). Hypermotility can lead to poor food absorption and to pathological conditions, such as irritable bowel syndrome (IBS). Intestinal motility is under the direct control of the Enteric Nervous System, a neuronal network that works autonomously and that is controlled also by the ECS.
In 1978, a study published in the Canadian Journal of Pharmacology showed that THC was able to reduce intestinal motility in guinea pigs. (13) Thirty years after, another study showed that cannabidiol (CBD), a non-psychotropic cannabinoid present in the Cannabis plant, was also able to reduce intestinal hypermotility induced by inflammation. (14)
The action of these phytocannabinoids, as well as that of the endocannabinoids and the synthetic cannabinoids, is mainly due to the stimulation of the CB1 receptors expressed in the Enteric Nervous System. (15) Once activated, CB1 reduces the release of acetylcholine (a neurotransmitters) from the enteric nerves and this, together with other mechanisms not fully understood, causes a decrease in intestinal contractility and therefore in motility. (15)
Not surprisingly, in the Handbook of Experimental Pharmacology, one of the most authoritative pharmacology journals in the world, CB1 receptors are called the physiological "brakes" of the GI system. (16)
The interaction with healthy bacteria
In the bowel, the ingested food is processed by the microbiota, that is by the billions of microorganisms - mostly bacteria, but also yeasts, viruses and others - which reside permanently in mammalian organisms. Microbiota helps in the processes of degradation and absorption of food and in the protection against infections. (17)
The ECS is able to modulate the composition of the microbiota and, consequently, its impact on GI physiology. The mechanism underlying this interaction is, however, still poorly understood.
In 2010, a study with mice with a genetic modification that induced obesity, found that the activation of the ECS by the microbiota - through an unclear mechanism - leads to an increase in fat mass, as a consequence of an increase in intestinal permeability. (18)
Conversely, the inhibition of the CB1 receptor reduces obesity and changes the composition of the microbiota, favoring the presence of protective bacterial species. (19) Probiotics, microorganisms which, if administered in the right quantities, have positive effects on intestinal pathophysiology, also interact with the ECS in the GI tract. (20)
In another study it has been shown that the administration of probiotics increases the activity of CB2 receptors and this effect was correlated with a decrease in abdominal pain and visceral hypersensitivity. (21)
The ECS and the microbiota are therefore able to influence each other and, since the mechanisms of this interaction are still unclear, further research could identify new pharmacological targets in diseases such as obesity and metabolic syndromes.
Eating is a pleasure with endocannabinoids
So far, we have described the fate of food in the GI system, from its intake to its absorption. To make this happen, however, people need to eat!
This means that one must feel that sense of hunger that pushes humans and animals, in the same way, to search for something to ingest, to meet the metabolic needs of the body, which require energy, provided right by the food. This process is called feeding behavior.
Since the ancient times, it is known that the ingestion of Cannabis, as well as the habit of smoking it, causes an increase in appetite, called "munchies". While in the past it was believed that to have munchies was only a suggestion due to the intoxication caused by Cannabis, scientists have discovered that this effect is real and depends on various mechanisms, both central and peripheral.
One of the mechanisms by which the ECS stimulates hunger was recently discovered. In their study, the researchers administered THC to laboratory mice and saw that they ate more and, oddly enough, had greater sensitivity to odors. After this experiment, the scientists used genetically modified mice, in which the CB1 receptor present in the olfactory bulb neurons was inactive. What happened next? Well yes, in these genetically modified animals, THC did not induce the sense of hunger. (22)
In 2015, the famous scientific journal Nature published another study on this topic, which highlighted a "paradoxical" mechanism by which the ECS regulates hunger. Scientists from Yale University, USA, studied the effect of the CB1 activation on the so-called pro-opiomelanocortinic (POMC) neurons. These neurons are activated when people are satiated, reducing the sense of appetite. Scientists therefore expected that by activating the CB1, which is known to be orexizing (which increases appetite), the activity of the POMC neurons would be reduced. Instead, the opposite happened. Scientist were then astonished but, without losing faith, analyzed their data more thoroughly and found that the POMC neurons, under normal conditions, release 2 substances: a hormone called α-Melanocyte-stimulating hormone, with an anorectic effect which blocks the appetite, and a neurotransmitter called beta endorphin, a substance that causes a high feeling of well-being (it acts on the opioid receptors). However, when the POMC neurons, as in the experiment, are activated by cannabinoids, they release only the beta endorphin and consequently there is no longer the anorectic effect of the hormone -but only the pleasant sensation released by the beta endorphin- and the appetite is not blocked. (23)
This and other similar researches highlight the role of endocannabinoids in what has been defined by scientists as "hedonistic hunger", or the search for food as pleasure, not as a requirement.
Significant in this sense is a work published in 2012 in the journal Neuropharmacology: scientists divided laboratory mice in two groups, one receiving sugar and another sugar plus THC; even if in both groups THC did not influence the amount of sugar consumed, mice that received THC showed a "hedonistic" reaction to food and in their brain the concentration of dopamine, a neurotransmitter involved in the mechanisms of gratification and reward, was increased; these effects induced by THC was abolished in the presence of a CB1 antagonist. (24)
This indicates, as reported by other studies, that the ECS is involved in the perception of the "acceptance" or not of a given food.
In this article we have seen how the ECS has a massive presence in the GI tract and how it is involved in the regulation of important functions, from the feeling of hunger to the absorption of food nutrients.
Acting on one of these mechanisms through the use of phytocannabinoids, cannabinoid-like drugs, antagonists or drugs that interfere with the biosynthesis or degradation of endocannabinoids, may prove to be an effective strategy in the treatment of numerous GI disorders, from functional disorders to obesity, from chronic inflammation to motility disorders.
1) Mechoulam R, Ben-Shabat S, Hanus L, et al. “Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors”. Biochem Pharmacol. 1995 Jun 29;50(1):83-90.
2) Pinto L, Izzo AA, Cascio MG, Bisogno T, Hospodar-Scott K, Brown DR, Mascolo N, Di Marzo V, Capasso F. “Endocannabinoids as physiological regulators of colonic propulsion in mice”.Gastroenterology. 2002 Jul;123(1):227-34.
3) Casu MA, Porcella A, Ruiu S, Saba P, Marchese G, Carai MA, Reali R, Gessa GL, Pani L: “Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract”. Eur J Pharmacol 459:97–105, 2003
4) Wright K, Rooney N, Feeney M, Tate J, Robertson D, Welham M, Ward S. “Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing”. Gastroenterology. 2005 Aug;129(2):437-53.
5) Pesce M, D’Alessandro A, Borrelli O, et al. Endocannabinoid‐related compounds in gastrointestinal diseases. J Cell Mol Med. 2018 Feb; 22(2): 706–715.
6) Esposito G, Capoccia E, Turco F, et al. “Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like re- ceptor 4-dependent PPAR-α activation”.Gut. 2014 Aug;63(8):1300-12.
7) Yamasaki T, Hemond C, Eisa M, et al. “The Changing Epidemiology of Gastroesophageal Reflux Disease: Are Patients Getting Younger?”. J Neurogastroenterol Motil. 2018 Oct 1;24(4):559-569.
8) Beaumont H, Jensen J, Carlsson A et al. “Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans”. Br J Pharmacol 12009;56:153–162.
9) Lehmann A, Blackshaw LA, Branden L. “Cannabinoid receptor agonism inhibits transient lower oesophageal sphincter relaxations and reflux in dogs”. Gastroenterology 2002;123:1129– 1134.
10) Sofia RD, Diamantis W, Edelson J. “Effect of Δ9-Tetrahydrocannabinol on the Gastrointestinal Tract of the Rat”. Pharmacology 1978; 17: 79-82.
11) Izzo AA, Capasso F, Costagliola A, et al. “An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice”. Gastroenterology. 2003 Sep;125(3):765-74.
12) Landi M, Croci T, Rinaldi-Carmona M, Maffrand JP et al. “Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabionoid Cb1 receptor”. Our J Pharmacol 2002;450:77-83.
13) Roth Sh. “Stereospecific presynaptic inhibitory effect of Δ9-tetrahydrocannabinol on cholinergic transmission in the myenteric plexus of the guinea pig”. Canadian Journal of Physiology and Pharmacology, 1978, 56(6): 968-975.
14) Capasso R, Borrelli F, Aviello G, Romano B, Scalisi C, Capasso F, Izzo AA. “Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice.” Br J Pharmacol. 2008 Jul;154(5):1001-8.
15) Coutts AA, Izzo AA. “The gastrointestinal pharmacology of cannabinoids: an update”. Curr Opin Pharmacol 2004;4:572–579.
16) Taschler U, Hasenoehrl C, Storr M, Schicho R. “Cannabinoid Receptors in Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance”. Handb Exp Pharmacol. 2017;(239):345.
17) Belkaid Y, Harrison OJ. “Homeostatic Immunity and the Microbiota”. Immunity 2017;46:562-576
18) Muccioli GG, Naslain D, Bäckhed F, et al. “The endocannabinoid system links gut microbiota to adipogenesis”. Mol Syst Biol. 2010 Jul;6:392.
19) Mehrpouya-Bahrami P, Chitrala KN, Ganewatta MS, et al. “Blockade of CB1 cannabinoid receptor alters gut microbiota and attenuates inflammation and diet-induced obesity”. Sci Rep. 2017 Nov 15;7(1):15645.
20) Forsythe P, Kunze WA. “Voices from within: gut microbes and the CNS”. Cell Mol Life Sci. 2013 Jan;70(1):55-69.
21) Rousseaux C1, Thuru X, Gelot A, Barnich N, Neut C, et al. “Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors”. Nat Med. 2007 Jan;13(1):35-7.
22) Soria-Gómez E, Bellocchio L, Reguero L, et al. “The endocannabinoid system controls food intake via olfactory processes”. Nature Neuroscience 2014:17; 407–415.
23) Koch M, Varela L, Kim JG, et al. “Hypothalamic POMC neurons promote cannabinoid-induced feeding”. Nature. 2015 Mar 5;519(7541):45-50.
24) De Luca MA, Solinas M, Bimpisidis Z, et al. “Cannabinoid facilitation of behavioral and biochemical hedonic taste responses”. Neuropharmacology 2012;63(1):161-168